Different breast cancer subtypes express peculiar CD44v—this diversity in CD44v expression has been ascribed to specific clinical markers (i.e., HER2, ER, PR), suggesting the involvement of CD44v in specific oncogenic signaling pathways [168]. Here, ESR1 is linked to breast carcinoma.